Table 3.
Published trials of directly selected donor-derived VSTs
| Virus | T-cell activator or capture | Patients | Antiviral effects | GVHD | Reference |
|---|---|---|---|---|---|
| IFN−γ capture | |||||
| EBV | Peptides derived from 11 EBV antigens | 6 | CR in 3 of 6 patients | None | 49 |
| EBV | EBNA-1 protein | 10 | CR in 7 of 10 patients | One grade 2 skin GVHD | 23 |
| CMV | CMV-pp65 protein | 18 | PR or complete response in 15 of 18 | One possible GVHD | 22 |
| CMV | Recombinant pp65 or pool of overlapping CMV-pp65 peptides | 18 | Eleven of 11 cleared disease | Five grade 1; 2 grade 2; 1 grade 3 acute GVHD | 38 |
| CMV | Two CMV-pp65 peptides | 6 | Six of 6 cleared CMV viremia | None | 50 |
| ADV | ADV antigen type C | 9 | Five of 6 evaluable had complete response or PR | One exacerbation of GVHD | 37 |
| ADV | ADV hexon protein | 30 | Twenty-one of 30 responded | Two with grade 1 GVHD | 51 |
| Multimer selection | |||||
| CMV | Peptides from CMV-pp65 or IE-1 | 9 | Eight of 9 cleared CMV | Two with grade 1 or 2 GVHD | 52 |
| CMV | Peptides from CMV-pp65 | 2 | Two of 2 CR | None | 53 |
| CMV | NLV-containing HLA-A02 pentamers | 2* | Two of 2 CR | None | 54 |